Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
16.66 USD | +1.03% | +13.18% | -0.89% |
Financials (USD)
Sales 2024 * | 462M | Sales 2025 * | 543M | Capitalization | 1.97B |
---|---|---|---|---|---|
Net income 2024 * | 117M | Net income 2025 * | 161M | EV / Sales 2024 * | 3.25 x |
Net cash position 2024 * | 469M | Net cash position 2025 * | 700M | EV / Sales 2025 * | 2.34 x |
P/E ratio 2024 * |
17.7
x | P/E ratio 2025 * |
12.9
x | Employees | 167 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 93.79% |
Latest transcript on Catalyst Pharmaceuticals, Inc.
1 day | +1.03% | ||
1 week | +13.18% | ||
Current month | +10.70% | ||
1 month | +8.25% | ||
3 months | +19.94% | ||
6 months | +22.05% | ||
Current year | -0.89% |
Managers | Title | Age | Since |
---|---|---|---|
Patrick McEnany
FOU | Founder | 76 | 01-12-31 |
Richard Daly
CEO | Chief Executive Officer | 62 | 15-02-18 |
Michael Kalb
DFI | Director of Finance/CFO | 53 | Dec. 31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Patrick McEnany
FOU | Founder | 76 | 01-12-31 |
Donald Denkhaus
BRD | Director/Board Member | 78 | 15-02-18 |
David Tierney
BRD | Director/Board Member | 60 | 02-09-30 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
1.05% | 28 M€ | -0.20% | ||
0.32% | 25 M€ | -1.16% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-15 | 16.66 | +1.03% | 1,161,513 |
24-05-14 | 16.49 | +1.66% | 1,006,785 |
24-05-13 | 16.22 | +1.76% | 1,465,974 |
24-05-10 | 15.94 | +1.85% | 1,437,077 |
24-05-09 | 15.65 | +6.32% | 1,780,987 |
Delayed Quote Nasdaq, May 15, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-0.89% | 1.97B | |
-0.07% | 91.42B | |
+2.76% | 41.08B | |
-9.06% | 34.26B | |
+55.32% | 25.27B | |
-16.61% | 15.27B | |
-9.14% | 12.81B | |
-12.11% | 11.6B | |
-43.61% | 11.42B | |
+7.79% | 9.16B |
- Stock Market
- Equities
- CPRX Stock